EmbarkNeuro
Biotechnology Research • 
Oakland, California, United States • 1-10 Employees
Company overview
| Headquarters | Oakland, California, United States |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at EmbarkNeuro
Ellis Wilson
Vice President Clinical Operations
About EmbarkNeuro
EmbarkNeuro is a neuroscience-focused biotech portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. EmbarkNeuro has a Phase II asset being evaluated in patients with major depressive disorder. The company was formed following the in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. At EmbarkNeuro, we are: patient-centric, collaborative, curious and courageous.
EmbarkNeuro revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
EmbarkNeuro has never raised funding before.
EmbarkNeuro Tech Stack
Discover the technologies and tools that power EmbarkNeuro's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Hosting
Reverse proxies
Programming languages
Miscellaneous
Blogs
JavaScript libraries
JavaScript libraries
Miscellaneous
Miscellaneous
Databases
Hosting
Canada
United Kingdom
China
Ireland
New Zealand
Lebanon
Frequently asked questions
4.8
40,000 users
